Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJRU | ISIN: US30233G2093 | Ticker-Symbol: PV3B
Tradegate
06.06.25 | 16:55
7,410 Euro
+2,66 % +0,192
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
EYEPOINT PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
EYEPOINT PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,5607,72817:32
7,5607,72817:32

Aktuelle News zur EYEPOINT PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.05.EyePoint advances with Duravyu Phase III trial4
30.05.H.C. Wainwright maintains Buy on EyePoint with $22 target4
EYEPOINT PHARMACEUTICALS Aktie jetzt für 0€ handeln
29.05.Analyst Expectations For EyePoint Pharmaceuticals' Future1
27.05.JPMorgan maintains EyePoint stock Overweight with $26 target7
27.05.JPMorgan behält Overweight-Rating für EyePoint-Aktie mit Kursziel von 26 US-Dollar bei11
27.05.EyePoint auf dem Stifel Forum: Strategische Fortschritte in der Augenheilkunde3
27.05.EyePoint Pharmaceuticals, Inc.: EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration168- Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest - - LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of...
► Artikel lesen
27.05.EyePoint Pharmaceuticals, Inc. - 8-K, Current Report1
16.05.EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)304WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients...
► Artikel lesen
16.05.Mizuho cuts EyePoint Pharmaceuticals target to $264
07.05.Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum8
07.05.EyePoint Pharmaceuticals, Inc. - 8-K, Current Report1
06.05.A Peek at EyePoint Pharmaceuticals' Future Earnings5
06.05.EyePoint Pharmaceuticals Q1 2025 Earnings Preview6
30.04.EyePoint Pharmaceuticals, Inc.: EyePoint to Report First Quarter 2025 Financial Results on May 7, 20255
16.04.EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)124WATERTOWN, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
► Artikel lesen
17.03.EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)304WATERTOWN, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
► Artikel lesen
06.03.Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews6
06.03.EyePoint Pharmaceuticals, Inc. - 10-K, Annual Report-
06.03.H.C. Wainwright maintains EyePoint stock Buy rating, $22 target3
Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1